Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice

BACKGROUND: Vaccines that block human-to-mosquito Plasmodium transmission are needed for malaria eradication, and clinical trials have targeted zygote antigen Pfs25 for decades. We reported that a Pfs25 protein-protein conjugate vaccine formulated in alum adjuvant induced serum functional activity i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Invest
Glavni autori: Healy, Sara A., Anderson, Charles, Swihart, Bruce J., Mwakingwe, Agnes, Gabriel, Erin E., Decederfelt, Hope, Hobbs, Charlotte V., Rausch, Kelly M., Zhu, Daming, Muratova, Olga, Herrera, Raul, Scaria, Puthupparampil V., MacDonald, Nicholas J., Lambert, Lynn E., Zaidi, Irfan, Coelho, Camila H., Renn, Jonathan P., Wu, Yimin, Narum, David L., Duffy, Patrick E.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2021
Teme:
Clinical Medicine
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8011888/
https://ncbi.nlm.nih.gov/pubmed/33561016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI146221
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items